

International Kidney Cancer Coalition (IKCC)

Board Directors / Medical Advisory Board Conflicts of Interest Form

Board Directors and members of the Medical Advisory Board have a legal obligation to act in the best interests of the International Kidney Cancer Coalition (IKCC), in accordance with the IKCC's Deed of Incorporation. The IKCC requires that all Board Directors and members of the Medical Advisory Board make full disclosure of all potential conflicts of interest that may arise where an individual's personal or family interests and/or loyalties, relationships, business transactions, presentations or publications conflict with those of the IKCC. Board Directors / Medical Advisory Board members and their relations by blood or marriage up to and including the third degree may not receive any direct or indirect personal benefit from deliveries to or agreements with the Coalition.

Please complete the following information and return this declaration to Julia@ikcc.org

Name: Inkeun Park


Job Title: Clinical Associate Professor, Asan Medical Center, Seoul, Korea

- I have no potential conflicts of interest to report. (Please sign and return the form)
- I have the following potential conflicts of interest to report

Please give details of the interest and whether it applies to yourself or, where appropriate, relations by blood or marriage up to and including the third degree, connected persons or some other close personal connection.

Category:	Please provide details: <i>[use additional page(s) as necessary]</i>
<input checked="" type="checkbox"/> Research Contracts	Industry-sponsored clinical trial: Abbvie, Astellas, Eli Lilly and Company, Ideaya biosciences, Merck, MSD, Pfizer, Roche, Selexcine, Research funding: Chong Kun Dang Pharmaceutical Co. and Boryung Pharmaceuticals Co
<input checked="" type="checkbox"/> Consulting, honoraria	Consulting or advisory role: Amgen Korea, Astellas Pharma Korea, BMS pharmaceutical Korea, Boryung Pharmaceuticals Co., Chong Kun Dang Pharmaceutical Co., Daiichi-Sankyo Korea, Janssen Korea, Merck, ONO pharmaceutical, and Samsung Bioepis.
<input type="checkbox"/> Employment in industry	
<input type="checkbox"/> Appointments such as trusteeships, directorships etc	
<input type="checkbox"/> Ownership in a healthcare company	
<input type="checkbox"/> Other financial or material support	
<input type="checkbox"/> Any other conflicts not covered by the above?	

Signature:



Date signed: 4-NOV-2023